How much funding has Nuvation Bio Inc. raised?

Nuvation Bio Inc. has raised $275.0M in total funding, most recently a Series A round.

Who are Nuvation Bio Inc.'s investors?

Nuvation Bio Inc.'s investors include Omega Funds, Aisling Capital, Altitude Life Science Ventures, Boxer Capital, The Baupost Group.

When was Nuvation Bio Inc. founded?

Nuvation Bio Inc. was founded in 2018.

Where is Nuvation Bio Inc. headquartered?

Nuvation Bio Inc. is headquartered in New York, New York, United States.

What industry is Nuvation Bio Inc. in?

Nuvation Bio Inc. operates in Biotech, Healthcare, Oncology.

How many employees does Nuvation Bio Inc. have?

Nuvation Bio Inc. has 51-200 employees.

Nuvation Bio Inc.

IPO

Nuvation Bio, Inc. | Oncology Drug Development

Public · New York, United States · Founded 2018 · $275.0M raised

Biotech

Healthcare

Oncology

Headquarters: New York, New York
Employees: 51–200
Founded: 2018
Business Model: B2B
Website: nuvationbio.com

Total Funding: $275.0M
Last Round: $275.0M Series AOct 2019
Rounds: 1
Type: Public

About

Nuvation Bio Inc. (NYSE: NUVB) is a global oncology company founded in 2018 by biopharma veteran David Hung, M.D. The company develops differentiated and novel oncology treatments through proprietary drug discovery programs and business development. Its lead product IBTROZI (taletrectinib) is FDA-approved for ROS1-positive non-small cell lung cancer. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai.

Summary

Nuvation Bio Inc. is a Biotech company based in New York, United States, founded in 2018. It has raised $275.0M in total across 1 round, most recently a $275.0M Series A round in Oct 2019. Investors include Omega Funds, Aisling Capital and Altitude Life Science Ventures.